Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories
Mandate

Vinge advises Atlas Antibodies on the acquisition of HistoCyte Laboratories

February 15, 2021 Banking and Finance Capital Markets and Public M&A M&A

Vinge advises Atlas Antibodies AB (majority owned by Patricia Industries, a part of Investor AB), in connection with its acquisition of HistoCyte Laboratories Ltd.

HistoCyte Laboratories’ portfolio of cell line materials provide control of immunohistochemical assays used in the diagnosis of cancer. The company has established a significant presence on important markets such as the UK and USA.

Closing is expected during early March 2021.

Vinge’s team consisted of Jonas Johansson together with Viktor Lennartsson (M&A), Albert Wållgren and Josefine Lanker (Banking and Finance) and Clara Sohlberg (Capital Markets and Public M&A).

Related

Vinge advises Chieftain Capital Management in connection with the investment in Koenigsegg Automotive

Vinge has advised Chieftain Capital Management, Inc. (”Chieftain”), a New York based family office, in its investment in the Swedish megacar manufacturer Koenigsegg Automotive AB (“Koenigsegg”).
October 08, 2024

Vinge advises iBinder Group in connection with the acquisition of Avima AB

Avima AB is a Swedish specialist in project and information management, with expertise in complex projects within construction, real estate and infrastructure.
October 07, 2024

Vinge advises Axcel in connection with the launch of Accru Partners, a new group within accounting, tax, audit and advisory services

 Vinge has advised the Nordic private equity firm Axcel in connection with its establishment of Accru Partners, a new group of 22 independent firms in Sweden within accounting, tax, audit and other advisory services.
October 04, 2024